Author(s): Gerber B, Loibl S, Eidtmann H, Rezai M, Fasching PA,
Abstract Share this page
Abstract BACKGROUND: We evaluated the pathological complete response (pCR) rate after neoadjuvant epirubicin, (E) cyclophosphamide (C) and docetaxel containing chemotherapy with and without the addition of bevacizumab in patients with triple-negative breast cancer (TNBC). PATIENTS AND METHODS: Patients with untreated cT1c-4d TNBC represented a stratified subset of the 1948 participants of the HER2-negative part of the GeparQuinto trial. Patients were randomized to receive four cycles EC (90/600 mg/m(2); q3w) followed by four cycles docetaxel (100 mg/m(2); q3w) each with or without bevacizumab (15 mg/kg; q3w) added to chemotherapy. RESULTS: TNBC patients were randomized to chemotherapy without (n = 340) or with bevacizumab (n = 323). pCR (ypT0 ypN0, primary end point) rates were 27.9\% without and 39.3\% with bevacizumab (P = 0.003). According to other pCR definitions, the addition of bevacizumab increased the pCR rate from 30.9\% to 41.8\% (ypT0 ypN0/+; P = 0.004), 36.2\% to 46.4\% (ypT0/is ypN0/+; P = 0.009) and 32.9\% to 43.3\% (ypT0/is ypN0; P = 0.007). Bevacizumab treatment [OR 1.73, 95\% confidence interval (CI) 1.23-2.42; P = 0.002], lower tumor stage (OR 2.38, 95\% CI 1.24-4.54; P = 0.009) and grade 3 tumors (OR 1.68, 95\% CI 1.14-2.48; P = 0.009) were confirmed as independent predictors of higher pCR in multivariate logistic regression analysis. CONCLUSIONS: The addition of bevacizumab to chemotherapy in TNBC significantly increases pCR rates.
This article was published in Ann Oncol
and referenced in Journal of Cytology & Histology